Not yet recruitingPhase 2NCT07021989

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

Studying Classic Hodgkin lymphoma

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Michael Spinner, MD
Principal Investigator: Michael Spinner, MD, MD
University of California, San Francisco
Intervention: Pembrolizumab(drug)
Enrollment: 38 enrolled
Eligibility: 18 years · All sexes
Timeline: 2026 – 2033

Study locations (6)

University of California Davis, Davis, California, United States
University of California San Francisco-Fresno, Fresno, California, United States
University of California Irvine, Irvine, California, United States
University of California, San Diego, La Jolla, California, United States
Unversity of California, Los Angeles, Los Angeles, California, United States
University of California, San Francisco, San Francisco, California, United States

Collaborators

UC Hematologic Malignancies Consortium (UCHMC) · Foresight Diagnostics, Inc. · Natera, Inc. · Gateway for Cancer Research

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07021989 on ClinicalTrials.gov

Other trials for Classic Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Classic Hodgkin lymphoma →

← Back to all trials